# Kriya Therapeutics, Inc.

> Kriya Therapeutics is a clinical-stage biopharmaceutical company building one-time, AAV-based gene therapies for prevalent chronic diseases of high unmet need. Founded in 2019 and headquartered in Morrisville, North Carolina with operations in Silicon Valley, Kriya pairs a proprietary, vertically integrated manufacturing and R&D engine with a pipeline spanning ophthalmology, metabolic disease, and neurology. Its bet: gene therapy shouldn't be reserved for the rare few, but engineered and manufactured at the scale and cost needed to reach millions.

- **Founded:** 2019
- **Headquarters:** Morrisville, North Carolina, United States
- **Founders:** Shankar Ramaswamy, MD (Co-Founder, Chairman & CEO), Roger Jeffs, PhD (Co-Founder & Vice Chairman), Fraser Wright, PhD (Scientific Co-Founder & Chief Gene Therapy Officer)
- **Team size:** Approximately 200 employees
- **Products:** Geographic Atrophy program, Thyroid Eye Disease program, Type 1 Diabetes program, MASH program, Trigeminal Neuralgia program
- **Notable:** Raised over $1.1 billion in total funding since 2019, Closed an oversubscribed $320M Series D in September 2025 at a significant step-up, Advanced five lead clinical pipeline programs across three therapeutic areas

## Products & services

- **Geographic Atrophy program** — Gene therapy in ophthalmology targeting geographic atrophy, an advanced form of age-related macular degeneration.
- **Thyroid Eye Disease program** — Ocular gene therapy for thyroid eye disease (TED).
- **Type 1 Diabetes program** — Metabolic gene therapy aimed at type 1 diabetes, supported by the T1D Fund.
- **MASH program** — Gene therapy for metabolic associated steatohepatitis (MASH), a chronic liver disease.
- **Trigeminal Neuralgia program** — Neurology gene therapy targeting trigeminal neuralgia, a chronic facial pain disorder.
- **Integrated manufacturing & R&D engine** — Proprietary, vertically integrated platform spanning product design, R&D, and GMP manufacturing, built to improve gene therapy purity, scale, and cost.

## Achievements

- Raised over $1.1 billion in total funding since 2019
- Closed an oversubscribed $320M Series D in September 2025 at a significant step-up
- Advanced five lead clinical pipeline programs across three therapeutic areas
- Built a fully integrated proprietary gene therapy manufacturing and R&D engine
- Assembled a leadership and scientific team drawing on early gene therapy pioneers

## Latest updates

- **2025-09** — Closed an oversubscribed $320M Series D co-led by Patient Square Capital and Premji Invest to advance five lead pipeline programs.
- **2024** — Added approximately $150M in fresh funding to support pipeline and manufacturing.

## Links

- Website: https://kriyatherapeutics.com
- LinkedIn: https://www.linkedin.com/company/kriyatx
- Twitter/X: https://twitter.com/kriyatx

---

Profile page: https://yespress.io/kriya-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-14